July 21, 2024
Antimicrobial Susceptibility Testing Market

Antimicrobial Susceptibility Testing Market Witnesses High Growth Owing to Increasing Antimicrobial Resistance by Pathogenic Bacteria and Fungi

The antimicrobial susceptibility testing market is estimated to be valued at US$ 3751.4 Mn in 2023 and is expected to exhibit a CAGR of 6.4% over the forecast period 2023 to 2030, as highlighted in a new report published by Coherent Market Insights.

Market Overview:

Antimicrobial susceptibility testing determines the sensitivity of pathogenic bacteria and fungi to different antimicrobial drugs. It plays a crucial role in effectively managing antimicrobial resistance by guiding clinicians to prescribe optimal therapeutic regimens. The increasing incidence of antimicrobial resistance shown by pathogens is a serious global health concern. Therefore, rapid and accurate antimicrobial susceptibility testing helps healthcare professionals optimize treatment outcomes.

Market Dynamics:

The Antimicrobial Susceptibility Testing Market is driven by the increasing threat of antimicrobial resistance shown by microbes. Persistent misuse and overuse of antimicrobial drugs for treating various conditions have led to emergence and spread of multidrug-resistant bacteria. According to the World Health Organization, antimicrobial resistance is one of the biggest threats to global health, food security, and development. Precise antimicrobial susceptibility testing helps curb resistance by selecting appropriate antimicrobial therapy. Moreover, continuous technological advancements are leading to development of automated, easy-to-use, and rapid susceptibility testing systems. This is further expected to support market growth over the forecast period.

SWOT Analysis

Strength: Testing products such as consumables, automated AST instruments, and culture media used in the market are highly reliable and accurate. The increasing prevalence of antimicrobial resistance is generating high demand for AST market. Advanced technologies are helping to get precise antimicrobial susceptibility test results in shorter turnaround time.

Weakness: High costs associated with automated AST instruments limit their accessibility. Lack of standard protocols for AST procedures can impact the reliability and comparability of test results.

Opportunity: Growing investments by market players as well as government bodies to develop rapid AST methods is expected to drive the market. Untapped emerging markets in Asia Pacific and Latin America regions provide growth opportunities.

Threats: Stringent regulatory framework in developed regions increases compliance costs for market players. Alternatives like whole genome sequencing-based AST methods can pose threats to traditional culture-based AST techniques.

Key Takeaways

The Global Antimicrobial Susceptibility Testing Market Size is expected to witness high growth, exhibiting CAGR of 6.4% over the forecast period, due to increasing incidence of infectious diseases and rising antimicrobial resistance.

Regional analysis

North America dominated the global market in 2023 and is expected to continue its dominance over the forecast period. This is attributed to presence of advanced healthcare infrastructure, rapid introduction of new AST methods and products and increasing funding for research activities in this field. Asia Pacific is poised to grow at the fastest CAGR over 2023-2030 due to large patient pool, healthcare improvements and growing awareness about AST.

Key players

Key players operating in the antimicrobial susceptibility testing market are Thermo Fisher Scientific Inc., BIOMÉRIEUX, HiMedia Laboratories, Alifax S.r.l. Italy, Creative Diagnostics, Resistell AG, Danaher, Becton, Dickinson and Company, Merck KGaA, Bio-Rad Laboratories, Inc., Bruker, Nissui Pharmaceutical Co., Ltd., F. Hoffmann-La Roche Ltd.,Synbiosis, Mast Group Ltd., ELITechGroup, Flinn Scientific, CONDALAB, Accelerate Diagnostics, Inc. and Zhuhai DL Biotech Co., Ltd.

 

*Note:
1. Source: Coherent Market Insights, Public sources, Desk research
2. We have leveraged AI tools to mine information and compile it